The REPLACE Trial: Treating Intermediate-Risk PAH by Substituting Just One Pill – American College of Cardiology -

Quick Takes Riociguat is a pulmonary vasodilator that works by directly stimulating soluble guanylate cyclase to produce cyclic guanosine monophosphate (cGMP). Patients with intermediate-risk pulmonary arterial hypertension (PAH) on a phosphodiesterase type 5 (PDE5) inhibitor with or without an endothelin-receptor antagonist (ERA) can achieve significant...